Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck

Albers, Andreas E.; Grabow, Regina; Qian, Xu; Jumah, Masen Dirk; Hofmann, Veit Maria; Krannich, Alexander; Pecher, Gabriele

doi:10.3892/mco.2017.1281

Cited by 24 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the phase III TAX323 trial which used induction CT with TPF regimen followed by RT, the CRR was 8.5% and ORR was 68% [ 16 , 17 ]. Albers et al [ 18 ] recently reported an overall response rate of 86% and 3-year survival of 65% using the docetaxel-based chemotherapy in combination in locally advanced cancer wherein 30/45 of his patients were treated with curative intent. Though role of neoadjuvant chemotherapy in head and neck cancers is debatable, however, recent evidence suggests some possible role.…”

Section: Discussionmentioning

confidence: 99%

Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma

et al. 2018

View full text Add to dashboard Cite

BackgroundHead and neck cancers are the commonest cancer in Southeast Asia. Despite being a surface cancer, it is associated with significant morbidity as despite early detection by the patients they often report for treatment late and hence are associated with poor prognosis. The role of neoadjuvant chemotherapy in head and neck cancer is still under evaluation; there is a large subgroup of population that does not respond to chemotherapy, and hence, most studies have failed to show any survival benefit. This study evaluated the role of neoadjuvant therapy with docetaxel and carboplatin in patients with oral cancer and correlated the response to human papilloma virus, EGFR1, EGFR2, and GADD45 expression.MethodsA total of 24 locally advanced, non-metastatic oral cancer patients were included in the study. Tumor biopsies were taken prior to the start of neoadjuvant therapy for expression of EGFR, Her-2-Neu, and GADD45 by immunohistochemistry and for HPV by PCR. The response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria after three cycles of chemotherapy. Statistical analysis was performed using correlation and Kaplan–Meier analysis; the difference in survival was calculated with log rank test.ResultsA total of 21 male and 3 female with a mean age of 53.12 years were enrolled. Sixty-five percent of these received three cycles of chemotherapy. Five patients were positive for HPV 16 and none for HPV 18. Twenty-two of 24 patients showed GADD45 expression, 3 showed expression of Her-2-Neu while all 24 showed expression for EGFR1 protein. Two-year overall survival was 81%; GADD45 expressions were found to significantly affect the overall and disease-free survival, while any of the other protein expression studied and HPV status was not significant.ConclusionThe result of the present study shows significant downgrading of the oral cancers with neoadjuvant chemotherapy suggesting its utility in borderline operable cases. However, the response of chemotherapy does not appear to be related to the expression of EGFR, Her-2-Neu, and GADD45 protein or presence of HPV. Bone involvement, perineural invasion, and GADD45 expression significantly predict OS and DFS. All patients who did not express Gadd45 died before 2 years. Study with more subjects and longer follow-up should be carried out to elucidate this relation further.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…HNSCC is regarded one of the most prevalent malignant diseases worldwide. Multimodal treatment strategies have substantially improved survival in patients with curative potential [ 6 – 9 ]. However, treatment decision in clinical routine especially for locally advanced (LA) HNSCC remains a challenge and is based on conventional factors such as tumor stage, comorbidities and a patient’s responses to ongoing treatments [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Aldehyde dehydrogenase 1 isoenzyme expression as a marker of cancer stem cells correlates to histopathological features in head and neck cancer: A meta-analysis

et al. 2017

Self Cite

View full text Add to dashboard Cite

There is a lack of predictive biomarkers that can identify patients with head and neck squamous cell carcinoma (HNSCC) who will experience treatment failure and develop drug resistance, recurrence, and metastases. Cancer stem-like cells (CSC) were identified as a subset of cells within the tumor in a variety of solid tumors including HNSCC. CSC are considered the tumor-initiating population responsible for recurrence or metastasis and are associated with therapy resistance. This meta-analysis including fourteen studies with altogether 1258 patients updates and summarizes all relevant data on the impact of ALDH1+ CSC on the prognosis of HNSCC and its association with clinicopathological parameters. ALDH1 expression is highly correlated with tumor differentiation (G3 vs. G1+G2; odds ratio = 2.85. 95% CI: 1.72–4.73, P<0.0001) and decreased overall survival (relative risk = 1.77. 95% CI: 1.41–2.22, P<0.0001) if one out of seven studies was excluded because of heterogeneity. These findings provide insights into the understanding of more aggressive tumor phenotypes and also suggest that the prognostic value provided by HNSCC-subtyping by CSC frequency warrant further clinical investigation.

show abstract

“…For example, one study has assessed the optimal dosing schedule of concurrent cisplatin in locally advanced HNSCC and demonstrates that cisplatin at 100 mg/ m 2 every 3 weeks performed better in loco-regional control, but with more toxicity, than cisplatin at 30 mg/m 2 weekly as adjuvant chemoradiotherapy 41. We found docetaxel in combination with cisplatin and 5‐fluorouracil effectively prolonged survival in patients with locally advanced and/or recurrent metastatic HNSCC with tolerable side effects 42. Taken together, a favorable safety profile with versatile anticancer effects is urgently needed to obtain curative therapeutic efficacy in aggressive cases.…”

Section: Discussionmentioning

confidence: 82%

Prognostic Score Predicts Survival in HPV-Negative Head and Neck Squamous Cell Cancer Patients

Qian¹,

Nguyen²,

Dong³

et al. 2019

Int. J. Biol. Sci.

Self Cite

View full text Add to dashboard Cite

Although patients having head and neck squamous cell carcinoma (HNSCC) have high mortality, standardized prognostic tools are unavailable. As such, having a validated simple prognostic scoring system to help predict mortality in these high-risk patients is urgently needed. The current study aimed to develop and internally validate a prognostic scoring system for overall mortality in human papillomavirus (HPV)-independent HNSCC patients. Data on 400 consecutive patients from the Cancer Genome Atlas database with a known HPV-RNA negative status were analyzed. A prognostic model to predict patient overall mortality was developed using the logistic regression beta coefficients and a simple risk score was created. The model was internally validated using bootstrap validation with 2000 replications. Five covariates (age, pT, pN, perineural invasion, and EAp53 score) were used in the development of the mortality risk score in the final model. Three risk groups were stratified based on the prognostic scores: low-risk (<96 points), medium-risk (96-121 points), and high-risk (≥122 points) with a survival of 76%, 62% and 35%, respectively. The proposed model presented good discrimination in both the development (AUC = 0.76; 95% CI 0.70, 0.81) and bootstrap validation (AUC = 0.76; 95% CI 0.70, 0.81) with a non-significant Hosmer-Lemeshow chi-square of 6.17 (p = 0.63). The proposed prognostic scoring system is easy to use to predict patient overall mortality and could also help in the appropriate allocation of medical resources while managing HNSCC patients. External validation (including re-calibration if needed) should be conducted to test the model's generalizability in different populations.

show abstract

Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck

Cited by 24 publications

References 19 publications

Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma

Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma

Aldehyde dehydrogenase 1 isoenzyme expression as a marker of cancer stem cells correlates to histopathological features in head and neck cancer: A meta-analysis

Prognostic Score Predicts Survival in HPV-Negative Head and Neck Squamous Cell Cancer Patients

Contact Info

Product

Resources

About